Technical Analysis for NVCR - NovoCure Limited

Grade Last Price % Change Price Change
grade B 48.87 -3.00% -1.51
NVCR closed down 3.0 percent on Monday, May 20, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical NVCR trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Cup with Handle Other 0.00%
NR7 Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Multiple of Ten Bullish Other -3.00%
Overbought Stochastic Strength -3.00%
Stochastic Reached Overbought Strength -2.84%
Multiple of Ten Bullish Other -2.84%
Overbought Stochastic Strength -2.84%
Multiple of Ten Bearish Other -0.79%

Older signals for NVCR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
Medicine Cancer Clinical Medicine Oncology Non Small Cell Lung Cancer Tumor Ovarian Cancer Pancreatic Cancer Glioblastoma Brain Tumor European Union Aging Associated Diseases Solid Tumor Cancers Mesothelioma
Is NVCR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 56.67
52 Week Low 26.02
Average Volume 477,922
200-Day Moving Average 43.0574
50-Day Moving Average 47.4054
20-Day Moving Average 47.255
10-Day Moving Average 49.035
Average True Range 1.8821
ADX 24.57
+DI 26.9734
-DI 17.9012
Chandelier Exit (Long, 3 ATRs ) 45.7037
Chandelier Exit (Short, 3 ATRs ) 47.3563
Upper Bollinger Band 51.8148
Lower Bollinger Band 42.6952
Percent B (%b) 0.68
BandWidth 19.298699
MACD Line 0.918
MACD Signal Line 0.5537
MACD Histogram 0.3643
Fundamentals Value
Market Cap 4.35 Billion
Num Shares 88.9 Million
EPS -1.09
Price-to-Earnings (P/E) Ratio -44.83
Price-to-Sales 13.08
Price-to-Book 13.88
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.97
Resistance 3 (R3) 51.10 50.54 50.62
Resistance 2 (R2) 50.54 50.00 50.47 50.50
Resistance 1 (R1) 49.70 49.67 49.42 49.57 50.39
Pivot Point 49.14 49.14 49.00 49.07 49.14
Support 1 (S1) 48.30 48.60 48.02 48.17 47.35
Support 2 (S2) 47.74 48.27 47.67 47.24
Support 3 (S3) 46.90 47.74 47.12
Support 4 (S4) 46.77